Nektar Therapeutics (NKTR) EBITDA Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Nektar Therapeutics (NKTR) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 7,045.00 |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -1,934.00 |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 7,261.00 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 9,003.00 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -2,649.00 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30,461.00 |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.76 Bn | 3.04 Mn | -17,110.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17,110.00 |
| Mar 31, 2026 | 26,425.00 |
| Dec 31, 2025 | 11,138.00 |
| Sep 30, 2025 | -3,879.00 |
| Jun 30, 2025 | 38,386.00 |
| Mar 31, 2025 | 4,382.00 |
| Dec 31, 2024 | 50,066.00 |
| Sep 30, 2024 | 31,346.00 |
| Jun 30, 2024 | 17,710.00 |
| Mar 31, 2024 | 29,889.00 |
| Dec 31, 2023 | 33,161.00 |
| Sep 30, 2023 | 15,730.00 |
| Jun 30, 2023 | -8,775.00 |
| Mar 31, 2023 | -35,960.00 |
| Dec 31, 2022 | 8,553.00 |
| Sep 30, 2022 | 10,810.00 |
| Jun 30, 2022 | -23,211.00 |
| Mar 31, 2022 | -4,195.00 |
| Dec 31, 2021 | -19,964.00 |
| Sep 30, 2021 | -10,054.00 |